India has earned the title of "pharmacy of the world" — and for good reason. The country produces roughly 20% of the global supply of generic medicines, exports pharmaceuticals to over 200 countries, and is home to the largest number of US FDA-approved manufacturing facilities outside the United States. But generic drug manufacturing, however essential, is fundamentally a low-margin, commoditized business. The future of pharma lies in innovation — novel biologics, biosimilars, advanced therapies, and precision medicine — and India has been underweight in this space for decades.

Biopharma SHAKTI, announced in Union Budget 2026-27 with an outlay of Rs 10,000 crore, is the government's most significant bet to change that. The initiative is designed to catalyze biopharmaceutical innovation, strengthen India's position in next-generation therapies, and create an ecosystem where pharma companies, biotech startups, and research institutions can collaborate to develop advanced drugs and treatments domestically.

Here is what Biopharma SHAKTI covers, who stands to benefit, and why it matters.

Understanding Biopharma SHAKTI

Biopharma SHAKTI sits within Budget 2026's broader manufacturing push — alongside the India Semiconductor Mission 2.0 and the expanded Electronics Component Manufacturing Scheme. The logic is consistent: India needs to move up the value chain in its strategic industries, and biopharmaceuticals represent one of the highest-value, highest-impact manufacturing categories.

The Rs 10,000 crore outlay is directed toward several interconnected objectives:

1. Biologics and Biosimilar Development

Biologics — complex drugs derived from living cells, including monoclonal antibodies, vaccines, and cell and gene therapies — are the fastest-growing segment of the global pharmaceutical market. The global biologics market is projected to exceed $600 billion by 2030. India's opportunity lies particularly in biosimilars — lower-cost versions of branded biologics whose patents have expired or are expiring.

India has already demonstrated capability in biosimilars. Biocon, Dr. Reddy's, and Zydus Lifesciences have launched biosimilar products in global markets. However, the development and regulatory approval of biosimilars requires specialized manufacturing infrastructure (cell culture facilities, purification systems, analytical labs) that is expensive and technically demanding. Biopharma SHAKTI provides capital support and infrastructure incentives to expand India's biosimilar manufacturing capacity.

2. Novel Drug Discovery

While India's strength has historically been in manufacturing rather than discovery, Biopharma SHAKTI explicitly aims to change this equation. The initiative supports:

  • Early-stage drug discovery programs at research institutions and startups
  • Clinical trial infrastructure to conduct Phase I, II, and III trials domestically at global standards
  • Regulatory science — building the CDSCO's (Central Drugs Standard Control Organisation) capacity to evaluate complex biologics and advanced therapies

India conducts a significant number of clinical trials — the country is consistently among the top five globally by trial volume — but the majority are Phase III trials sponsored by multinational pharma companies. Biopharma SHAKTI aims to increase the proportion of India-originated trials, where Indian companies and institutions are the sponsors developing novel molecules.

3. Advanced Therapy Platforms

Some of the most exciting developments in modern medicine fall under the umbrella of advanced therapies:

CAR-T Cell Therapy: Cancer immunotherapy using chimeric antigen receptor T-cells has shown remarkable results in treating certain blood cancers. However, CAR-T treatments currently cost $300,000-500,000 per patient in the US, making them inaccessible to the vast majority of patients globally. Indian institutions — including IIT Bombay and the Tata Memorial Centre — are working on developing affordable CAR-T therapies that could cost a tenth of US prices. Biopharma SHAKTI provides funding support for these programs.

Personalized Cancer Vaccines: mRNA technology, validated during the COVID-19 pandemic, is now being applied to develop personalized cancer vaccines that train the immune system to attack specific tumor mutations. While this field is dominated by US and European companies (BioNTech, Moderna), Indian research institutions and biotech startups are beginning to build capabilities. The 2026 initiative provides a framework for accelerating this work.

Gene Therapy and Gene Editing: CRISPR-based therapies are moving from lab to clinic globally. India's role in this space is nascent but growing, with research programs at CSIR labs, IITs, and private biotech companies. Biopharma SHAKTI's support for advanced therapy platforms is forward-looking — these technologies may take 5-10 years to reach commercial scale in India, but the investment needs to start now.

India's Pharmaceutical Industry: The Context

To appreciate why Biopharma SHAKTI matters, it helps to understand the current state of India's pharmaceutical sector:

Market Size: India's pharmaceutical market is valued at approximately $50 billion domestically and exports another $25+ billion annually. It is the world's third-largest pharmaceutical producer by volume and 14th by value — the gap between volume ranking and value ranking tells the story of India's position in low-cost generics.

Generic Drug Dominance: India supplies 50-60% of global generic medicine demand and approximately 40% of generic demand in the United States specifically. Companies like Sun Pharmaceutical, Cipla, Lupin, Dr. Reddy's, Aurobindo, and Zydus Lifesciences are global leaders in generic manufacturing.

The Innovation Gap: Despite its manufacturing prowess, India spends a relatively small proportion of pharma revenue on R&D — typically 6-8% for the largest companies, compared to 15-20% for global innovators like Roche, Pfizer, or Johnson & Johnson. This underinvestment in R&D is the fundamental constraint that Biopharma SHAKTI aims to address.

Healthcare Spending: India spends approximately 2.1% of GDP on healthcare (World Bank), one of the lowest rates among major economies. This constrains public funding for drug development and limits the domestic market's ability to pay for innovative therapies. However, the flip side is that the unmet medical need is enormous, creating a powerful demand signal for affordable innovation.

Who Can Benefit from Biopharma SHAKTI?

Established Pharmaceutical Companies

India's top pharma companies are the most obvious beneficiaries. Companies that have already invested in biologics capabilities — Biocon (and its subsidiary Biocon Biologics), Dr. Reddy's, Zydus Lifesciences, Cipla, and Serum Institute of India — can leverage Biopharma SHAKTI's incentives to expand their biosimilar pipelines and invest in novel drug programs.

For mid-sized pharma companies that have been primarily focused on generics, Biopharma SHAKTI provides a financial bridge to invest in biologics infrastructure. The capital requirements for building a biologics manufacturing facility (typically $200-500 million) have been a barrier for these companies. Government co-investment through the scheme can make these projects viable.

Biotech Startups

India's biotech startup ecosystem has grown significantly but remains small relative to the US, Europe, and China. Key constraints include:

  • High capital requirements for drug development (typically $50-100 million to take a molecule through clinical trials)
  • Long development timelines (8-12 years from discovery to market)
  • Limited biotech-specific VC funding compared to software startups
  • Regulatory complexity in navigating clinical trials and approvals

Biopharma SHAKTI addresses several of these barriers by providing grants, co-investment, and infrastructure access (shared lab facilities, GMP manufacturing capacity) that reduce the capital burden on startups. The initiative also aims to create a more supportive regulatory environment through CDSCO capacity building.

Notable Indian biotech startups that could benefit include companies working on:

  • Novel antibody therapies
  • mRNA and nucleic acid therapeutics
  • Microbiome-based treatments
  • AI-driven drug discovery (combining pharma expertise with India's AI talent)
  • Point-of-care diagnostics

Research Institutions

India has a network of pharmaceutical and biomedical research institutions — CSIR-CDRI, NIPER (National Institute of Pharmaceutical Education and Research), ICMR labs, IITs, and leading medical colleges — that produce significant research but struggle to translate it into commercial products. The "valley of death" between academic research and commercial drug development is a global problem, but it is particularly acute in India due to limited translational research funding.

Biopharma SHAKTI creates explicit pathways for research institutions to collaborate with industry partners to advance promising molecules from the lab to clinical trials. This academic-industry bridge is essential for building India's drug discovery capabilities.

The Broader Health Innovation Context

Biopharma SHAKTI does not exist in isolation. Several parallel trends are shaping India's health innovation landscape:

Mental Health Technology

The mental health apps market is growing at 20% annually through 2030, driven by increasing awareness of mental health issues, smartphone penetration, and the acute shortage of mental health professionals in India (fewer than 1 psychiatrist per 100,000 population in most states). While not directly funded by Biopharma SHAKTI, the initiative's support for neurological and psychiatric drug development complements the digital mental health ecosystem.

Alternative Proteins and Nutrition

Global alternative protein investments exceeded $5 billion in 2024, and India is a growing market for plant-based and fermentation-derived food products. At the intersection of nutrition science and pharmaceutical innovation, there are opportunities in medical nutrition, nutraceuticals, and food-as-medicine approaches that Biopharma SHAKTI's broader framework could support.

Digital Health Integration

The convergence of biopharma with digital health — AI-powered drug discovery, digital biomarkers, remote patient monitoring during clinical trials, real-world evidence generation — is accelerating. India's strength in IT services and AI, combined with Biopharma SHAKTI's funding for drug development, creates a unique opportunity for digitally-enabled biopharmaceutical innovation.

How Startups and Companies Can Access the Funding

While detailed implementation guidelines for Biopharma SHAKTI are still being finalized, based on the budget announcement and comparable government schemes, the likely access pathways include:

1. Direct Application to the Scheme: Companies and startups meeting eligibility criteria (investment commitments, R&D spending, manufacturing plans) can apply for capital subsidies, tax incentives, and grant funding under the scheme.

2. Through Research Collaboration: By partnering with ICMR, CSIR, or other government research institutions, companies can access co-funded research programs that combine public research capabilities with private development expertise.

3. Biotechnology Industry Research Assistance Council (BIRAC): BIRAC, under the Department of Biotechnology, is likely to be a key implementing agency for Biopharma SHAKTI. BIRAC already runs several funding programs (BIG, SBIRI, CRS) for biotech startups and is well-positioned to manage the expanded budget.

4. Industry Consortia: For large-scale projects (e.g., building shared biologics manufacturing infrastructure), industry consortia that pool resources from multiple companies may be eligible for enhanced incentives.

5. International Collaboration: Biopharma SHAKTI is expected to encourage partnerships between Indian companies and international pharma firms. Joint ventures, technology licensing agreements, and collaborative clinical trial programs with global companies can serve as pathways to access the scheme's benefits.

Job Creation and Skill Development

The biopharmaceutical sector is a high-value employer. Unlike generic drug manufacturing, which is relatively labor-intensive but lower-skilled, biologics manufacturing and drug discovery require:

  • PhD-level scientists in molecular biology, biochemistry, immunology, and pharmacology
  • Bioprocess engineers who can design and operate cell culture and purification systems
  • Clinical research professionals for trial management and regulatory affairs
  • Quality assurance specialists with expertise in biologics GMP requirements
  • Data scientists for AI-driven drug discovery and clinical data analysis

Biopharma SHAKTI's job creation potential is estimated at 25,000-50,000 direct high-skilled jobs and several times that in indirect employment. The initiative also includes provisions for skill development — partnerships with universities to develop specialized curricula, fellowship programs for PhD students in biopharmaceutical sciences, and industry-academia exchange programs.

This focus on human capital is critical. India's pharma workforce is large (over 2 million people) but skewed toward generic manufacturing roles. Building a biopharmaceutical innovation ecosystem requires a fundamental upgrade in the skill profile of the workforce.

International Context and Collaboration

India's biopharmaceutical ambitions intersect with global trends in several ways:

Global Supply Chain Diversification: Post-COVID, every major economy is seeking to diversify its pharmaceutical supply chains. India, as an established pharmaceutical manufacturer with scale capabilities, is a natural partner for countries looking to reduce dependence on any single source. Biopharma SHAKTI strengthens India's value proposition by moving it from "we can manufacture your generics" to "we can co-develop and manufacture your biologics."

Patent Expirations: The next five years will see a wave of patent expirations for major biologic drugs (Humira, Stelara, Keytruda, and others), representing tens of billions of dollars in biosimilar opportunities. Indian companies that can bring high-quality biosimilars to market quickly will capture significant value. Biopharma SHAKTI's manufacturing incentives are timed to coincide with this wave.

Global Pharma Partnerships: Multinational pharmaceutical companies are increasingly looking to India not just for manufacturing but for research collaboration. The cost advantage (clinical trials in India cost 40-60% less than in the US) combined with a large, diverse patient population makes India attractive for clinical development. Biopharma SHAKTI creates a framework for structured international collaboration.

Challenges and Risks

Biopharma SHAKTI is ambitious, and its success is not guaranteed. Several risks and challenges merit attention:

Execution and Disbursement: Government schemes often face challenges in timely fund disbursement and complex application processes. If Biopharma SHAKTI gets bogged down in bureaucratic approval processes, its impact will be diminished.

Regulatory Capacity: CDSCO's ability to evaluate complex biologics and advanced therapies at global standards is a critical bottleneck. Even with funding, if the regulatory approval process is slow or unpredictable, drug development timelines will extend and investor confidence will erode.

Intellectual Property Environment: India's IP regime — particularly around pharmaceutical patents — has been a point of contention with global pharma companies (the Novartis-Glivec case remains a landmark precedent). While India's compulsory licensing provisions serve public health goals, they can create uncertainty for companies investing in novel drug development. Balancing innovation incentives with access priorities will require careful policy calibration.

Market Access and Pricing: Even if India develops innovative biologics, the domestic market's ability to pay premium prices is limited given low healthcare spending. Successful commercialization will require either export-focused strategies or creative pricing models (tiered pricing, outcomes-based contracts, government procurement).

The Vision: From Pharmacy of the World to Innovation Hub

Biopharma SHAKTI's significance extends beyond the Rs 10,000 crore allocation. It represents a strategic pivot for India's pharmaceutical sector — from being the world's most efficient drug manufacturer to aspiring to be a global source of pharmaceutical innovation.

This transformation will not happen in a single budget cycle. Building drug discovery capabilities, advanced manufacturing infrastructure, and regulatory expertise is a decade-long endeavor. But every journey needs a clear starting point, and Biopharma SHAKTI provides one — with meaningful financial commitment, identified focus areas, and institutional frameworks.

For the pharmaceutical companies, biotech startups, research institutions, and investors who position themselves correctly, the opportunity is substantial. India has the talent, the manufacturing base, and now the policy support. The question is execution.

The pharmacy of the world is ready to become its innovation lab.

Suggested Internal Links:

Call to Action: Building health-tech or biopharma solutions? CoderCops helps biotech and pharmaceutical companies with digital transformation, AI integration, and technology platform development. Reach out to our team to explore how we can support your innovation journey.

Comments